Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 11/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | VEGFA | P15692 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PDE1A | P54750 | 1/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atizoram SCHEMBL14418236 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL7270902 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL450389 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL5083334 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL13016486 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL14473158 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL450388 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL7270904 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL20883039 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 | |
| Atizoram SCHEMBL3416683 | 1.00 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0428302-B1 | Enzymatic resolution of endo-bicycle(2.2.1)-heptan-2-ol and derived pharmaceutical agents | PFIZER (US) | 1997-09-24 | — | — | EP | claimed |
| EP-0428313-B1 | Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders | PFIZER (US) | 1994-02-02 | — | — | EP | claimed |
| US-5270206-A | Enzymatic resolution of endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents | PFIZER INC. (US) | 1993-12-14 | — | — | US | claimed |
| EP-0428302-A2 | Enzymatic resolution of endo-bicycle(2.2.1)-heptan-2-ol and derived pharmaceutical agents | PFIZER INC. (US) | 1991-05-22 | — | — | EP | claimed |
| WO-2015068142-A2 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS, USES AND METHOD OF MANAGEMENT OF MYELOPROLIFERATIVE DISORDER | CELLWORKS GROUP, INC. (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20060083714-A1 | Combination of a pde iv inhibitor and a tnf-alpha antagonist | PHARMACIA CORPORATION | 2006-04-20 | — | — | US | disclosed |
| CN-1431194-A | Synthesis of 5-(3-[exo-dicyclo [2,2,1] heptyl-2-ylidene oxy]-4-methoxy phenyl)-3,4,5,6-tetrahydropyrimidine-2 (1H) ketonic intermediate, and its prepn. process | PFIZER (US) | 2003-07-23 | — | — | CN | disclosed |
| CN-1431195-A | Synthesis of 5-(3-[exo-dicyclo [2,2,1] heptyl-2-ylidene oxy]-4-methoxy phenyl)-3,4,5,6-tetrahydropyrimidine-2 (1H) ketonic intermediate and its prepn. process | PFIZER (US) | 2003-07-23 | — | — | CN | disclosed |
| US-6399776-B2 | Processes and intermediates in the synthesis of 5-(3-exo-bicyclo[2.2.1]hept-2-yloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyrimidine-2(1H)-one | PFIZER INC | 2002-06-04 | — | — | US | disclosed |
| US-6399776-B2 | Processes and intermediates in the synthesis of 5-(3-exo-bicyclo[2.2.1]hept-2-yloxy-4-methoxyphenyl)-3,4,5,6-tetrahydropyrimidine-2(1H)-one | PFIZER INC | 2002-06-04 | — | — | US | disclosed |
| US-20010041798-A1 | Processes and intermediates in the synthesis of 5-(3-{exo-bicyclo{2.2.1}hept-2-yloxy]-4-methoxyphenyl)-3,4,5,6- tetrahydropyrimidin-2(1H)-one | LACOUR THOMAS G (US) | 2001-11-15 | — | — | US | disclosed |
| US-20010041798-A1 | Processes and intermediates in the synthesis of 5-(3-{exo-bicyclo{2.2.1}hept-2-yloxy]-4-methoxyphenyl)-3,4,5,6- tetrahydropyrimidin-2(1H)-one | LACOUR THOMAS G (US) | 2001-11-15 | — | — | US | disclosed |
| EP-0775119-A1 | PROCESSES AND INTERMEDIATES IN THE SYNTHESIS OF 5-(3- EXO-BICYCLO 2.2.1]HEPT-2-YLOXY]-4-METHOXYPHENYL)-3,4,5,6-TETRAHYDROPYRIMIDIN-2(1H)-ONE | PFIZER INC. (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004253-A1 | PROCESSES AND INTERMEDIATES IN THE SYNTHESIS OF 5-(3-[EXO-BICYCLO[2.2.1]HEPT-2-YLOXY]-4-METHOXYPHENYL)-3,4,5,6-TETRAHYDROPYRIMIDIN-2(1H)-ONE | PFIZER INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| WO-1996004253-A1 | PROCESSES AND INTERMEDIATES IN THE SYNTHESIS OF 5-(3-[EXO-BICYCLO[2.2.1]HEPT-2-YLOXY]-4-METHOXYPHENYL)-3,4,5,6-TETRAHYDROPYRIMIDIN-2(1H)-ONE | PFIZER INC. (US) | 1996-02-15 | — | — | WO | disclosed |
| US-5461056-A | Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders | PFIZER INC. (US) | 1995-10-24 | — | — | US | disclosed |
| US-5395935-A | Endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents | PFIZER INC. (US) | 1995-03-07 | — | — | US | disclosed |
| US-5342842-A | Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders | PFIZER INC. (US) | 1994-08-30 | — | — | US | disclosed |
| US-5270206-A | Enzymatic resolution of endo-bicyclo[2.2.1]heptan-2-ol and derived pharmaceutical agents | PFIZER INC. (US) | 1993-12-14 | — | — | US | disclosed |
| EP-0428302-A2 | Enzymatic resolution of endo-bicycle(2.2.1)-heptan-2-ol and derived pharmaceutical agents | PFIZER INC. (US) | 1991-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060083714-A1 | Combination of a pde iv inhibitor and a tnf-alpha antagonist | TNF, PDE4A, PDE3B | PDE4A 2/4885PDE4B 5/4885PDE4C 9/4885 |
| US-20010041798-A1 | Processes and intermediates in the synthesis of 5-(3-{exo-bicyclo{2.2.1}hept-2-yloxy]-4-methoxyphenyl)-3,4,5,6- tetrahydropyrimidin-2(1H)-one | EXOC3, EXOC4, EXOC1 | PDE4A 1712/4885PDE4B 1090/4885PDE4C 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.